Eli Lilly is just weeks away from launching Mounjaro ... The agency has approved a four-dose version of the drug, called Mounjaro KwikPen, which provides a month’s course of GLP-1 and GIP ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025 ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

LLY PE Ratio (Forward) data by YCharts. Given the popularity of GLP-1 drugs and the potential for an oral GLP-1 drug launch in 2026, Lilly remains very well positioned. As such, I think the stock ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large cap dividend growth stocks. Investors continue to favor large-cap stocks ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving ...